ArticleFree radical biology & medicine2025
Xanthine oxidoreductase expression is diminished in breast cancer as a response to uric acid mediated chelation of redox active iron.
Article in Free radical biology & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SLC2A9-Mediated Uric Acid Homeostasis Modulates Apoptosis in TNBC.Breast cancer (Dove Medical Press) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Breast cancer patients with diminished xanthine oxidoreductase (XOR) expression have a greater risk for metastases and diminished survival; however, the mechanisms underpinning this phenomenon are unknown. Under normal growth conditions, neither triple negative MDA-MB-231 nor ER-positive MCF-7 cells demonstrated detectable expression of XOR mRNA, protein and enzymatic activity, which was confirmed using archived in silico data. Enforced expression of XOR did not yield viable cells with significant increases in XOR protein and activity. In addition, exposing breast cancer cells to clinically relevant concentrations of UA diminished growth, migratory capacity, and clonogenic cell survival. Parallel experiments with iron chelators (e.g., DTPA or DFO) produced similar effects, suggesting a potential link between UA and iron chelation. Consistent with this hypothesis, the breast cancer cell growth inhibition seen with UA was inhibited by supplementing iron (2.0 μM). Electron paramagnetic resonance (EPR) spectrometry confirmed that UA loosely chelated iron by diminishing Fe-mediated redox reactions with ascorbate (e.g., Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.